|[February 06, 2013]
Agios Pharmaceuticals to Present at the Leerink Swann 2013 Global Healthcare Conference
CAMBRIDGE, Mass. --(Business Wire)--
Agios Pharmaceuticals, the leading biopharmaceutical company focused on
discovering and developing novel drugs in the fields of cancer
metabolism and rare metabolic genetic diseases, today announced that
David Schenkein, M.D., chief executive officer, is scheduled to present
at the Leerink Swann 2013 Global Healthcare Conference on Wednesday,
February 13, 2013 at 3:00PM EST at the Waldorf Astoria Hotel in New York
Dr. Schenkein is expected to discuss the company's portfolio of cancer
metabolism therapeutics, itsexpansion into targeting inborn errors of
metabolism, and the assets and capabilities that position Agios as a
leader in dysregulated metabolism.
About Agios Pharmaceuticals, Inc.
Agios is the leading biopharmaceutical company focused on discovering
and developing novel drugs in the fields of cancer metabolism and rare
metabolic genetic diseases. In addition to an active research and
discovery pipeline across both therapeutic areas, Agios has multiple
first-in-class programs in cancer metabolism and inborn errors of
metabolism advancing toward the clinic. All Agios programs focus on
genetically identified patient populations leveraging our knowledge of
metabolism, biology and genomics. For more information, please visit our
website at www.agios.com.
[ Back To Technology News's Homepage ]